TAK Earnings Date: Feb 4, 2027 (Estimated) — Takeda Pharmaceutical Company Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is TAK's next earnings date?
Takeda Pharmaceutical Company Limited (TAK) is expected to report Q3 2026 earnings on Thursday, February 4, 2027 at 2:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.56 on revenue of $7.75B.
How did TAK do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q2 2026), Takeda Pharmaceutical Company Limited posted EPS of $1.96 versus the $0.14 estimate, a beat of 1251.7%. Revenue was $15.29B against a $7.34B estimate. The stock's 1-day post-earnings move was -0.7%.
How much does TAK stock move after earnings?
TAK beat EPS estimates in 4 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 2.5% (up or down) in the day after earnings.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
🤖 AI Earnings Analysis
Takeda’s launch momentum and pipeline milestones anchor a strong first half, with revenue up 427.6% to $15.3B and EPS at $1.96. However, unusually large growth and estimate beats merit caution; FY2026 guidance remains $29.6B revenue and $3.01 EPS.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q2 2026 | 0.14 | 1.96 | +1251.72% | $15.29B | ✅ Beat | -0.69% | — | — |
| 2026-07-30 | Q1 2026 | 0.39 | 0.48 | +23.85% | $7.65B | ✅ Beat | -2.82% | -5.80% | +1.58% |
| 2026-05-13 | Q4 2025 | 0.21 | 0.28 | +35.24% | $6.98B | ✅ Beat | +1.34% | +0.97% | -3.35% |
| 2026-01-29 | Q3 2025 | 0.55 | 0.47 | -13.64% | $7.60B | ❌ Miss | +2.92% | +6.32% | +12.33% |
| 2025-10-30 | Q2 2025 | 0.44 | 0.43 | -2.27% | $7.52B | ❌ Miss | -3.90% | -1.33% | +4.71% |
| 2025-07-30 | Q1 2025 | 0.47 | 0.52 | +11.06% | $7.66B | ✅ Beat | -5.05% | -0.79% | +3.75% |
| 2025-01-30 | Q3 2024 | — | 0.44 | — | $7.51B | — | +2.92% | +0.39% | +8.21% |
| 2024-10-31 | Q2 2024 | 0.57 | 0.45 | -21.05% | $7.90B | ❌ Miss | +0.38% | -0.76% | -1.97% |
Showing last 8 quarters.
Revenue by segment & region
By segment
FY2025 · $4.51T total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Gastroenterology | 31.2% | $1.41T | +3.7% | $697.90B | $777.80B | $875.68B | $1.09T |
| PDT Immunology | 23.5% | $1.06T | +2.4% | $394.17B | $420.39B | $506.95B | $678.44B |
| Rare Diseases | 16.9% | $762.70B | +1.3% | $634.89B | $591.75B | — | $723.44B |
| Oncology | 12.9% | $580.13B | +3.5% | $420.96B | $416.51B | $468.73B | $438.74B |
| Neuroscience | 9.2% | $414.34B | -26.8% | $438.52B | $417.30B | $482.29B | $637.71B |
| Other Product | 5.0% | $223.96B | -13.0% | $704.76B | $574.07B | $624.15B | $454.60B |
| Vaccines | 1.3% | $59.61B | +7.6% | — | — | — | — |
By region
FY2025 · $4.43T total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 48.9% | $2.16T | -9.0% | $1.60T | $1.57T | $1.71T | $2.10T |
| Europe And Canada | 25.9% | $1.15T | +8.6% | $645.53B | $666.18B | $739.17B | $842.67B |
| JAPAN | 9.8% | $433.11B | +3.5% | $592.79B | $559.75B | $658.98B | $512.04B |
| Latin America | 5.7% | $254.13B | +7.8% | $143.46B | $121.64B | $128.47B | $160.38B |
| CHINA | 4.4% | $195.14B | +1.8% | — | — | — | — |
| Other Countries Not Separately Reported | 3.0% | $133.89B | +3.9% | $71.26B | $68.52B | $68.94B | $95.18B |
| Asia, Excluding Japan And China | 2.2% | $98.67B | -0.7% | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.